Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease.
Saini L, Brandwein J, Turner R, Larratt L, Hamilton M, Peters A, Wu C, Zhu N, Patterson JM, Bolster L, Mant M, Ritchie B, Liew E, Ghosh S, Sandhu I. Saini L, et al. Among authors: liew e. Eur J Haematol. 2016 Nov;97(5):471-478. doi: 10.1111/ejh.12757. Epub 2016 May 3. Eur J Haematol. 2016. PMID: 27028202
Incremental value of the bone marrow trephine biopsy in detecting residual leukemia following treatment for Acute Myeloid Leukemia.
Saini L, Brandwein J, Turner R, Larratt L, Hamilton M, Peters A, Wu C, Zhu N, Taparia M, Patterson JM, Bolster L, Mant M, Ritchie B, Liew E, Mirza I, Quest G, Nahirniak S, Ghosh S, Sandhu I. Saini L, et al. Among authors: liew e. Leuk Res. 2016 Jun;45:47-52. doi: 10.1016/j.leukres.2016.04.005. Epub 2016 Apr 8. Leuk Res. 2016. PMID: 27092851
Changing frontline AML treatment patterns from 2013 to 2022.
Brandwein JM, Ebeling K, Ding L, Liew E, Zhu N, Bolster L, Hamilton M, Hnatiuk M, Wang P. Brandwein JM, et al. Among authors: liew e. Leuk Res. 2023 Sep;132:107354. doi: 10.1016/j.leukres.2023.107354. Epub 2023 Jul 12. Leuk Res. 2023. PMID: 37467567
Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.
Kim DDH, Novitzky-Basso I, Kim TS, Atenafu EG, Forrest D, Savoie L, Bence-Bruckler I, Keating MM, Busque L, Delage R, Xenocostas A, Liew E, Paulson K, Stockley T, Laneuville P, Lipton JH, Kamel-Reid S, Leber B. Kim DDH, et al. Among authors: liew e. Br J Haematol. 2021 May;193(4):779-791. doi: 10.1111/bjh.17447. Epub 2021 Apr 20. Br J Haematol. 2021. PMID: 33876423 Clinical Trial.
BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase.
Kim DDH, Kim TS, Atenafu EG, Novitzky Basso I, Forrest D, Bence-Bruckler I, Savoie L, Busque L, Keating MM, Delage R, Xenocostas A, Liew E, Paulson K, Stockley T, Laneuville P, Lipton JH, Kamel-Reid S, Leber B. Kim DDH, et al. Among authors: liew e. Br J Haematol. 2022 Jan;196(1):136-145. doi: 10.1111/bjh.17807. Epub 2021 Sep 8. Br J Haematol. 2022. PMID: 34496035
82 results